Jump to content
RemedySpot.com

NATAP: 3 New HIV Drugs Discoveries

Rate this topic


Recommended Posts

Posted

New HIV Drugs DiscoveriesVIR-576 is a new type of HIV entry inhibitor, it works differently than T20 or maraviroc so cross-ressistance does not appear to be a concern, viral load reduction looks pretty good in the first data in an HIV+ patient group in the study linked t below, it is however administered by injection so authors of study said they are trying to develop an oral administration. BMS licensed a new NRTI for development which the data below linked to which was presented at recent conferences reports good antiviral activity, good safety profile, and a resistance profile suggesting utility in patients with NRTI experience. The 3rd discovery reported here is much earlier in development, it has only been researched in the lab and finds interesting interactions between HIV proteins that might lead to a drug.New Drug Strategy VIR-576, HIV Entry Inhibitor Against gp41 Fusion) Shows Promise Against HIV - (12/23/10)VIR-576

(Active substance against HIV infection), New HIV Entry Inhibitor Against gp41 Fusion Peptide - VIRO Pharmaceuticals GmbH & Co. KG - (12/23/10)Discovery suggests new way to prevent HIV from infecting human cells (Vif & APOBEC3F) - (12/23/10)Bristol-Myers

Squibb and Oncolys BioPharma Enter Global Licensing Agreement for Investigational HIV Compound (Festinavir, OBP-601, NRTI) - (12/22/10)A Phase-Ib/IIa dose-escalation study for evaluation of the safety ...Background: OBP-601 is a novel NRTI with in vitro activity against several wild type and ... OBP-601 is a weak inhibitor of mitochondrial DNA synthesis. ...www.natap.org/2010/ICAAC/ICAAC_53.htmDrug Susceptibility Profile of OBP-601, a novel NRTI, Using a ...OBP-601

(4'-Ed4T) is a novel nucleoside analog with potent anti-HIV-1 activity and limited cellular toxicity, which has a unique in vitro resistance profile ...www.natap.org/2010/newsUpdates/122210_05.htmA Single-dose Escalation Study to Evaluate the Safety ...Background: OBP-601

is a novel NRTI (derivative of stavudine, d4T) with potent in vitro anti-HIV activity against several wild type HIV-1 subtypes and ...www.natap.org/2009/CROI/croi_85.htm=

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...